Compare Abeona Therapeutics Inc (ABEO) vs Essex Property Trust, Inc. (ESS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Essex Property Trust, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Essex Property Trust, Inc. trades at $292.66 (market cap $19.17B). The key difference: Essex Property Trust, Inc. is far larger — about 51.4× Abeona Therapeutics Inc's market cap, and Essex Property Trust, Inc. pays a 3.47% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ESS | |
|---|---|---|
Market Cap | $373.32M | $19.17B |
Sector | Health | Real Estate |
52-Week High | $7.23 | $298.33 |
52-Week Low | $4.17 | $239.61 |
Enterprise Value | $228.22M | $25.89B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Essex Property Trust (ESS) trades at $298.32, showing minimal daily change. The stock exhibits a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported robust earnings, beating estimates for three consecutive quarters, with Q2 2026 EPS expected at $1.47. Revenue reached $1.89B in 2025, supported by high gross and net income margins. Recent developments include a $2.59 dividend declaration and inclusion in the Russell Microcap Index.
Outlook remains positive due to strong West Coast rental demand and AI-driven employment growth, but risks include high debt levels and Seattle market weakness. Analyst consensus is mixed with a $291.68 price target, suggesting limited upside from current levels. Investment appeal hinges on sustained rental growth and balance sheet management amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →
